Degarelix
- Generic Name
- Degarelix
- Brand Names
- Firmagon, Degarelix Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C82H103ClN18O16
- CAS Number
- 214766-78-6
- Unique Ingredient Identifier
- SX0XJI3A11
- Background
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone s...
- Indication
Degaralix is used for the management of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- -
Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT03193645
- Locations
- 🇫🇷
Hopital de la Source (there may be multiple sites in this country), Orléans, France
Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2017-03-15
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 90
- Registration Number
- NCT03080116
- Locations
- 🇧🇪
University Hospitals Leuven, Leuven, Vlaams-brabant, Belgium
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 612
- Registration Number
- NCT03070886
- Locations
- 🇺🇸
Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸MyMichigan Medical Center Saginaw, Saginaw, Michigan, United States
Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.
- Conditions
- Interventions
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 52
- Registration Number
- NCT03069937
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT03056638
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Safety and Efficacy of Firmagon® (Degarelix) for Injection
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 368
- Registration Number
- NCT02886598
- Locations
- 🇰🇷
Gangnam Severance Hospital (there may be other sites in this country), Seoul, Korea, Republic of
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 22
- Registration Number
- NCT02849990
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2024-11-05
- Target Recruit Count
- 885
- Registration Number
- NCT02799706
- Locations
- 🇧🇪
Hopitaux Universitaires Bordet-Erasme - Hopitaux Universitaires Bordet- Institut Jules Bordet, Brussels, Belgium
🇧🇪Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 230
- Registration Number
- NCT02726009
- Locations
- 🇮🇳
Shalby Hospital, Ahmedabad, India
🇮🇳HealthCare Global Enterprises Limited, Bangalore, India
🇮🇳Bodyline Hospitals, Ahmedabad, India
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 545
- Registration Number
- NCT02663908
- Locations
- 🇸🇰
Fakultna nemocnica Nitra, Nitra, Slovakia
🇺🇸Erlanger Health System, Chattanooga, Tennessee, United States
🇨🇦J. Giddens Medicine Professional Corporation, Brampton, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.